ESMO Breast 2021 | Highlights from ESMO Breast 2021
Volkar Mueller, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, talks on important updates from the European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021, including updated data on trastuzumab deruxtecan and the incidence of interstitial lung disease associated with this approach. Dr Mueller also highlights the novel Trop-2 targeting antibody-drug conjugate which represents a promising therapeutic approach for these patients. This interview took place at the virtual ESMO Breast Cancer Congress 2021.
Disclosures
Volkar Mueller, MD, has received speaker honoraria from Amgen, Astra Zeneca, Daiichi-Sankyo, Eisai, Pfizer, MSD, Novartis, Roche, Teva and Seattle Genetics; has received consultancy honoraria from Genomic Health, Hexal, Roche, Pierre Fabre, Amgen, ClinSol, Novartis, MSD, Daiichi-Sankyo, Eisai, Lilly, Tesaro and Nektar; has received institutional research support from Novartis, Roche, Seattle Genetics and Genentech; and has received travel grants from Roche, Pfizer and Daiichi Sankyo.
